As shown in Figure 4, six tumor antigens (THBS2, FSTL3, TNNT1, BGN, CTHRC1, and NOX4) were identified as potential therapeutic candidates for the anti-CRC mRNA vaccine that can be processed and presented by APCs to activate a robust immune response. This evidence concerns the gene THBS2 and neoplasm.